Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06382233
Recruiting Observational

The PRO-FUTURE Project

NCT06382233 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-01-30
Last updated
2024-04-30

Condition(s) studied

Ureteropelvic Junction ObstructionChronic Kidney Diseases

Investigational drug(s) / intervention(s)

Identification of Diagnostic Biomarkers

Identification of Diagnostic Biomarkers: Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.

Study summary

The goal of this observational study is to learn about specific biomarkers of unilateral ureteropelvic junction obstruction (UPJO) in children undergoing surgical intervention for unilateral UPJO compared with controls. The main question it aims to answer are:

* Are Urinary single-cell and extracellular vesicles (EVs) screening useful to stage the intrarenal injury and repair processes in UPJO babies?
* Do babies with unilateral UPJO have a whole blood gene expression profiling (WBGEP) allowing an accurate unilateral UPJO diagnosis?

Eligibility

Sex
ALL
Min age
1 Day
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * unilateral UPJO * 0-5years of age Exclusion Criteria: * bilateral UPJO * previous surgical intervention on the urinary tract * bladder or lower urinary tract symptoms or malformations * nephro- or urolithiasis, vesicoureteral reflux * urinary tract infections.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Univeristà degli Studi della Campania Luigi Vanvitelli Naples Campania Recruiting
Department of Clinical Sciences and Community Health, University of Milano Milan Italy Active Not Recruiting
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico Milan Italy Recruiting
Obstetrics and Gynecology Unit, University of Modena and Reggio Emilia Modena Italy Recruiting
AORN Santobono-Pausilipon Naples Italy Recruiting

More University of Campania Luigi Vanvitelli trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06382233 on ClinicalTrials.gov ↗ ← All trials in Italy